Current strategies focus on gradual titration and long-term tolerability, especially when combined with other peptides like semaglutide or tirzepatide
Summary Patients with type 2 diabetes and cardiovascular disease should be started on either a GLP-1RA, SGLT-i, or both in high-risk cases, while simultaneously tapering any prescribed insulin regimen
References Ligita T, Wicking K, Francis K, Harvey N, Nurjannah I
Publications (1) Journal Impact Factor Most Recent Mol Carcinog Quercetin inhibits endothelial & hepatocellular carcinoma cell crosstalk via reducing extracellular vesicle-mediated VEGFR2 mRNA transfer
Given semaglutide's 7-day half-life (Kapitza et al., J Clin Pharmacol, 2015), injecting 0.25 mg every 10 to 14 days maintains a lower average steady-state concentration than weekly dosing